|

Soluble B7-H3 as a Biomarker for Osteosarcoma

RECRUITINGSponsored by Peking University People's Hospital
Actively Recruiting
SponsorPeking University People's Hospital
Started2023-06-05
Est. completion2024-07-01
Eligibility
Age12 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05942456

Summary

Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.

Eligibility

Age: 12 Years+Healthy volunteers accepted
Inclusion Criteria:

* High Grade osteosarcoma verified with pathologic diagnosis.
* systemic treatment-naive before the first time Blood drawing.
* ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy.
* All radiographs are complete for clinical evaluation.

Exclusion Criteria:

* Patients who Can't tolerate blood drawing.
* Patients without complete medical records in PKUPH system.
* Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy.
* other conditions that investigators think are not suitable for this study.

Conditions5

BiomarkerCancerOsteosarcomaProgressionSurveillance

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.